Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease

New Microbiologica

Volumn 33, Issue 2, 2010, Pages 117-127

  Anar, Ceyda ^a   Bicmen, Can ^a   Yapicioglu, Sena ^a   Unsal, Ipek ^a   Halilcolar, Huseyin ^a   Yilmaz, Ufuk ^a  

^a Izmir Chest Diseases and Surgery Training Hospital   (Turkey)

Author keywords

Antibody response; Clinical evaluation; COPD; Influenza; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICS; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VACCINATION;

EID: 77952694281     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. BELSHE R.B., SWIERKOSZ E.M., ANDERSON E.L., NEWMAN F.K., NUGENT S., MAASSAB H.F. (1992). Immunization of infants and young children with live attenuated trivalan COPD-recombinant Influenza A/H1N1, H3N2 and B vaccine. J. Infect. Dis. 165, 727-732.
2. BENNE CA., KRAAIJEVELD C.A., VAN STRDP J.A.G. (1995). Interactions of surfactant protein A with Influenza A viruses: Binding and neutralization. J. Infect. Dis. 171, 335-341.
3. BRYDAK L.B., MACHALA M. (2000). Humoral immune response to influenza vaccination in patients from high risk groups. Drugs. 60, 35-53. (Pubitemid 30601315)
4. BTS GUIDELINE. (2001). The management of chronic obstructive pulmonary disease Eur. Respir. J. 18, 60-66.
5. CAO Z., ONG K.C., ENG P., TAN W.C., NG T.P. (2006). Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology. 11, 188-195.
6. CDC (2008). Influenza activity-United States and worldwide, 2007-08 season. MMWR 57, 692-697.
7. CENTERS FOR DISEASE CONTROL AND PREVENTION. (2009). Serum cross-reactive antibody response to a novel influenza A (H1N1 ) virus after vaccination with seasonal infl uenza vaccine. MMWR Morb. Mortal. Wkly Rep. 58, 521-524.
8. CENTERS FOR DISEASE CONTROL AND PREVENTION. (2009). Update: infections with a swine origin influenza A (HlNl) virus - United States and other countries, April 28, 2009. MMWR Morb. Mortal. Wkly Rep. 58, 431-433.
9. DONNER C.F. (1999). Infectious exacerbations of chronic bronchitis. Monaldi Arch. Chest Dis. 54, 43-48.
10. DEMICHELI V., RIVETTI D., DEEKS J. J., JEFFERSON T.O. (2004). Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. CD001269.
11. ELDEN L.J.R., NIJHUIS M., SCHIPPER P., SCHURRMAN R., LOON A.M. (2001). Simultaneous detection of influenza viruses A and B using real- time quantitative PCR. J. Clin. Microbiol. 39, 196-200. (Pubitemid 32059590)
12. GOVAERT T.M., THUS C.T, MASUREL N., SPRENGER M.J., DINANT G.J., KNOTTNERUS J.A. (1994). The efficacy of influenza vaccination in elderly individuals: a randomized double- blind placebo-controlled trial. JAMA. 272, 1661-1665. (Pubitemid 24359136)
13. GROSS P.A., HERMOGENES A.W., SACKS H.S., LALL J., LEVANDOWSKI R.A. (1995). The efficacy of influenza in elderly persons. Ann. Intern. Med. 125, 518-552.
14. GARTEN R.J., DAVIS C.T., RUSSELL C.A., SHU B., LINDSTROM S., BALISH A., ET AL. (2009). Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 325, 197-201.
15. HAK W., HOES A.W., GROBBEE D.E. (2003). Conventionalinfluenza vaccination is not associated with complications in working-age patients with asthma or chronic obstructive pulmonary disease. Am. J. Epidemiol. 157, 692-700.
16. IMMUNOBIOLOGICAL LABORATORIES (2008). Influenza A and B Ig A, Ig M and Ig G ELISA v3.5: instruction manuals. IBL-Hamburg GmbH, Hamburg, Germany (http://www.ibl-hamburg.com).
17. JAWETZ E., MELNICK J., ADELBERG E.A., BROOKS G.F., BUTEL J.S., ORNSTON L.N. (1989). Medical Microbiology. 18th ed. East Norwalk, CT: PrentinceHall, Appleton and Lange. 467-478.
18. JOHANSEN K., NICOLL A., CIANCIO B.C., KRAMARZ P. (2009). Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill. 14, 19361.
19. KOSITANONT U., RAWEEWAN K., WASI C., WONGSURAKIAT P., SUTHAMSMAI T., MARANETRA N. (2004). Occurence and protective level of influenza infections using serology in patients with COPD in vaccination study. J. Med. Assoc. Thai. 87, 964-969.
20. KESHTKAR-JAHROMI M., VAKILI H., RAHNAVARDI M., GHOLAMIN S., RAZAVI S.M., ESKANDARI A., SADEGHI R., VATAN-POUR H., KESHTKAR-JAHROMI M., HAGHIGHAT B., GHAFFARIPOUR M., MOKHTARI-AZAD T. (2009). Antibody response to influenza immunization in coronary artery disease patients: a controlled trial. Vaccine [Epub ahead of print].
21. LEINDCKI P.O., PASSILA S. (1977). Quantitative, semiautomated, enzyme-linked immunosorbent assay for viral antibodies. J. Infect. Dis. Oct; 136 Suppl: S294-S299.
22. LAURIE B. (2009). Seasonal Flu Vaccine May Help Protect Against H1N1. B.M.J. Published online October 6, 2009. (http://www.medscape.com/vie-warticle/ 710106-print)
23. MURPHY B.R., CLEMENTS M.L., XIERNEY E.T., ROBERT E.B., STBENBERG J., CHANOCK R.M. (1985). Dose response of Influenza A/Washington/897/80 (HN) avian -human reassortant virus in adult volunters. J. Infect Dis. 152, 225-229.
24. MURRAY C.J.L., LOPEZ A.D. (1997). Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet. 349, 1498-1504. (Pubitemid 27216360)
25. MAZZONE P.J., MOSSAD S.B., MAWHORTER S.D., MEHTA A.C., SCHILZ R.J., MAURER J.R. (2001). The humoral immune response to influenza vaccination in lung transplant patients. Eur. Respir. J. 18, 971-976 (Pubitemid 34092871)
26. MENON B., GURNANI M., AGGARWAL B. (2008). Comparison of outpatient visits and hospitalizations, in patients with chronic obstructive pulmonary disease, before and after influenza vaccination. Int. J. Clin. Pract. 62, 593-598. (Pubitemid 351348025)
27. NICHOL K.L., MARGOLIS K.L., WUONRENMA J., STENBERG T.V. (1994). The efficay and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331, 778-784.
28. NIEDERMAN M.S. (1997). COPD - the role of infection. Chest 112, 301S-2.
29. NICHOL K.L., WUORENMA J., STENBERG T.V. (1998). Benefits of influenza vaccination for low-intermediate and high-risk senior citizens. Arch. Intern. Med. 158, 1769-1776
30. NICHOL K.L., BAKEN L., NELSON A. (1999). Relation between influenza vaccination and outpatient visits hospitalization, and mortality in elderly patients chronic lung disease. Ann. Intern. Med. 130, 397-403.
31. WHO WORKSHOP REPORT. (2003). Global Initative for Chronic Obstructive Lung Disease, 1-100.
32. ROTHBARTH R.H., KEMPEN B.M., SPRENGER M.J.W. (1995). Sense and nonsence of influenza vaccination in asthma and COPD. Am. J. Respir. Crit. Care Med. 1551, 1682-1686.
33. RAMADAN P.A., ARAUJO F.B., JUNIOR M.F. (2001). A 12month follow up of influenza vaccination campaign based on voluntary adherence: report on upper respiratory symptoms among volunteers and non volunteers. Sao Paulo Med. 119, 142-145.
34. SNYDER M.H., BANKS S., MURPHY B.R. (1988). Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay. J. Infect. Dis. 26, 2034-2040.
35. SENEFF M.G., WAGNER D.P., WAGNER R.P., ZIMMERMAN J.E., KNAUS WA. (1995). Hospital and 1-year survival of patients admitted to intensive careunits with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 274, 1852-1857.
36. SAYAN M., GENC S., YUCE A., UCAN E., YULUG N. (2005). ELISA for monitoring seroconversion in individuals vaccinated with influenza virus vaccine. Turkish Journal of Infection. 19, 25-29. (Turkish).
37. SCHULTZE V., D'AGOSTO V., WACK A., NOVICKI D., ZORN J., HENNIG R. (2008). Safety of MF59 adjuvant. Vaccine. 26, 3209-3222.
38. TURKISH THORACIC SOCIETY COPD STUDY GROUP GUIDELINE. (2000). The Diagnosis and treatment of COPD. 1, 1-25 (Turkish).
39. TASBAKAN M.S., PULLUKCU H., SlPAHI H., IŞTKGÖZ M. (2007). The evaluation of influenza vaccination rate and knowledge about influenza vaccination in patients with chronic obstructive pulmonary disease. Turkish Journal of Infection. 21, 89-92 (Turkish).
40. WISELKA M. (1994). Influenza: diagnosis, manangement and prophylaxis. BMJ. 308, 1341-1345.
41. WONGSURAKIAT P., LERTAKYAMANEE J., MARANETRA K.N., JONGRIRATANAKUL S., SANGKAEW S. (2003). Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J. Med. Assoc. Thai. 86, 497-508.
42. WONGSURAKIAT P., MARANETRA K., KOSITANONT U., DEJSOMRTTRUTAI W., CHAROENRATANAKUL S. (2004). Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination. Chest. 125,2011-2020.
43. TING Z., CARDONA C.J. (2009). Preexisting immunity to pandemic (H1N1) 2009 [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Nov [date cited]. Available from http://www.cdc.gov/EID/con-tent/15/11/1847.htm.